CRO/Sponsor

Life can change in an instant, but there is one thing that always abides: hope.

Options have emerged that make DIY EDC technology more accessible to smaller organizations.

The region has an appropriate population size, solid infrastructure, experienced nvestigators, and short timelines.

A survey of clinical research professionals asked: What makes you a successful project leader?

Conversion from paper to ePRO for an instrument designed to assess diabetes' impact on quality of life.

Modeling and simulation has been heralded for some time as a possible answer to the industry's woes.

Demonstrating biosimilarity is highly dependent on the unique characteristics of the product.

From tactical to strategic: tracking the evolution of global clinical supply chain management.

A well designed CTCP can keep everyone motivated and focused on achieving trial objectives.

The major industry milestones of the past 20 years.

The adoption of new, consistent definitions are needed to help demystify late phase trials.

Continual change is coming as sponsors' sourcing requirements diverge from the major CROs.

Where do CRO's turn next? What does pharma do about it?

Cancer trial recruitment is struggling-adult participation is limited.

Optimizing early phase trials key to the success of novel cytotoxics and targeted therapies.

Are emerging markets the only answer to oncology clinical trial recruitment?

Where do CRO's turn next? What does pharma do about it?

Continual change is coming as sponsors' sourcing requirements diverge from the major CROs.

Researchers who work on HIV vaccines face a major challenge: convincing members of at-risk communities to volunteer for these trials.

Partnering with CROs and using a blinded independent central review can increase trial success.

Guatemala is multi-ethnic, multilingual, and multi-cultural-ideal for international trials.

Research shows four factors best predict successful patient enrollment in clinical trials.

BRIC governements are working to make it easier to conduct trials in country.

Drug, biological supply, and medical device manufacturers must track all payments of over $10.

Knowledge is power, but power is of no value if you don't exercise it.